Imetelstat Combination Therapy
A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
What's the purpose of the trial?
Accepting patients
For Healthcare Professionals Only
This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.
Participating Centers
There are 9 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Cytarabine is an antineoplastic chemotherapy agent that is FDA approved to treat several different kinds of leukemia.
- Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
- Hydrocortisone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
- Imetelstat is a first in class telomerase inhibitor that is being studied for use in several different cancers.
- Leucovorin is a form of folic acid that is typically given after certain types of chemotherapy to protect against side effects.
- Methotrexate is a chemotherapy medication that may be used in the treatment of many different cancers.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.